Replies to post #3000 on Sesen Bio Inc (SESN)

[averytheindian]

It's odd that this press release is Just a few days after the failed Phase 3 clinical trial.
Could they be setting up to seize an opportunity?


Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis

Eleven Biotherapeutics, Inc. (EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced top-line results from the Phase 3 clinical trial of its lead drug candidate, isunakinra (EBI-005), for the treatment of severe allergic conjunctivitis. In this trial, there were no statistically significant differences between the isunakinra treated group and the vehicle control group on the primary endpoint of ocular itching or on any secondary endpoints. Isunakinra was generally well tolerated, with 94% of the patients completing the trial and there were no serious adverse events reported.